AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10913225 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA) 300 mg
Number of subjects: 26
Study 10913225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AA (300 mg), EPA (110 mg), and DHA (400 mg)
Number of subjects: 26
Study 10913225 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented control
Number of subjects: 26
Study 8704095 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 beta
Number of subjects: 40
Study 8704095 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-alpha
Number of subjects: 40
Study 1526682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime (CDZ) 2 g i.v. once daily for seven days
Number of subjects: 51
Study 1526682 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid 1 g daily i.v. for one week (Control)
Number of subjects: 51
Study 4035227 — intervention group
Group type: EXPERIMENTAL
Intervention: sulodexide
Number of subjects: 0
Study 30708260 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 8
Study 30708260 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 8
Study 29672831 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg riluzole
Number of subjects: 18
Study 29672831 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg retigabine
Number of subjects: 18
Study 29672831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26969416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 to 40 mg
Number of subjects: 15800
Study 26969416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 to 40 mg
Number of subjects: 15800
Study 26969416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 15800
Study 26969416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 and 40 mg
Number of subjects: 15800
Study 24207098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial clot retrieval with the Solitaire FR device after intravenous tissue plasminogen activator
Number of subjects: 0
Study 24207098 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tissue plasminogen activator alone
Number of subjects: 0
Study 22354851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1274
Study 22354851 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 1274
Study 20385940 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-millisecond Pascal PRP
Number of subjects: 24
Study 20385940 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-millisecond Pascal PRP
Number of subjects: 24
Study 18724539 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine (Gemzar) plus 3 mg/kg of infliximab (Remicade)
Number of subjects: 86
Study 18724539 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine (Gemzar) plus 5 mg/kg of infliximab (Remicade)
Number of subjects: 86
Study 18724539 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine (Gemzar) plus placebo
Number of subjects: 86
Study 16521701 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1,800 mg/d with vitamin E 300 mg/d and vitamin C 600 mg/d
Number of subjects: 10
Study 16521701 — intervention group
Group type: COMPARATOR
Intervention: Control group (vitamin E 300 mg/d and vitamin C 600 mg/d without EPA)
Number of subjects: 10
Study 12173322 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat screening flexible sigmoidoscopy
Number of subjects: 10164
Study 10459062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical application of 5‐aminolevulinic acid (5‐ALA)
Number of subjects: 0
Study 7843707 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (40 micrograms/h)
Number of subjects: 160
Study 7843707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 2370508 — intervention group
Group type: EXPERIMENTAL
Intervention: Large cuff (15 X 33 cm)
Number of subjects: 242
Study 2370508 — intervention group
Group type: COMPARATOR
Intervention: Small cuff (12 X 23 cm)
Number of subjects: 242
Study 654296 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenformin
Number of subjects: 10
Study 654296 — intervention group
Group type: EXPERIMENTAL
Intervention: Buformin
Number of subjects: 10
Study 654296 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 10
Study 654296 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of biguanide treatment
Number of subjects: 10
Study 31950141 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) for 8 weeks
Number of subjects: 209
Study 31950141 — intervention group
Group type: COMPARATOR
Intervention: Weight loss maintenance diets based on protein and glycemic index content
Number of subjects: 209
Study 30621974 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + ticagrelor
Number of subjects: 68
Study 30621974 — intervention group
Group type: COMPARATOR
Intervention: Aspirin + clopidogrel
Number of subjects: 68
Study 30621974 — intervention group
Group type: COMPARATOR
Intervention: Registry cohort (Aspirin + clopidogrel)
Number of subjects: 68
Study 29047326 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of Community Health Workers (CHWs) in diabetes group visits
Number of subjects: 50
Study 29047326 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CHWs)
Number of subjects: 50
Study 29047326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (with CHWs)
Number of subjects: 50
Study 26324329 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/day add-on to dapagliflozin plus metformin
Number of subjects: 315
Study 26324329 — intervention group
Group type: COMPARATOR
Intervention: Placebo add-on to dapagliflozin plus metformin
Number of subjects: 315
Study 24929184 — intervention group
Group type: EXPERIMENTAL
Intervention: Low flavanol apple puree (25 mg epicatechin)
Number of subjects: 25
Study 24929184 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavanol apple puree (100 mg epicatechin)
Number of subjects: 25
Study 24929184 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (75 mg)
Number of subjects: 25
Study 24929184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both low and high flavanol apple purees
Number of subjects: 25
Study 23033226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led warfarin self-management program
Number of subjects: 114
Study 23033226 — intervention group
Group type: COMPARATOR
Intervention: Standard management at the anticoagulation clinic
Number of subjects: 114
Study 19900743 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer evaluation group (students evaluated each other's performance before switching roles)
Number of subjects: 78
Study 19900743 — intervention group
Group type: COMPARATOR
Intervention: Control group (students worked in a defined doer-helper relationship without peer evaluation)
Number of subjects: 78
Study 17641565 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (minimum of four needles, electroacupuncture preferred, strong electrical stimulation to needles placed in muscle, course of at least 10 treatments)
Number of subjects: 13
Study 17641565 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 13
Study 15882556 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg/day
Number of subjects: 85
Study 15882556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 12522677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy with carboplatin plus ACNU (arm A)
Number of subjects: 30
Study 12522677 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy with cisplatin plus BCNU (arm B)
Number of subjects: 30
Study 10321140 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear
Number of subjects: 0
Study 10321140 — intervention group
Group type: EXPERIMENTAL
Intervention: Fränkel functional appliance
Number of subjects: 0
Study 7664215 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 3700
Study 7664215 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 to 100 mg once daily
Number of subjects: 3700
Study 7664215 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily + 12.5 mg HCTZ
Number of subjects: 3700
Study 7664215 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 3700
Study 2693078 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 liters of Golytely
Number of subjects: 300
Study 2693078 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 liters of Golytely combined with Cascara‐Salax
Number of subjects: 300
Study 2693078 — intervention group
Group type: EXPERIMENTAL
Intervention: X‐Prep (a Senna preparation) combined with an enema
Number of subjects: 300
Study 354042 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily doses of acebutolol
Number of subjects: 20
Study 354042 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acebutolol with chlorexolone
Number of subjects: 20
Study 29923537 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to second-hand smoke at home in urban areas, females, low educational status, and nongovernment employees
Number of subjects: 510
Study 29923537 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to second-hand smoke at workplace in rural areas, males, primary and middle education, and nongovernment or self‐employed occupation
Number of subjects: 510
Study 27037905 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary trabeculotomy
Number of subjects: 28
Study 27037905 — intervention group
Group type: COMPARATOR
Intervention: Combined trabeculectomy-trabeculotomy (CTT) with mitomycin C (MMC)
Number of subjects: 28
Study 24891081 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced night-wakings (four prolonged awakenings across 8h in bed)
Number of subjects: 61
Study 24891081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (4h in bed)
Number of subjects: 61
Study 24891081 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep night
Number of subjects: 61
Study 22702049 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum sealing drainage (VSD) combined with anti-taken skin graft
Number of subjects: 60
Study 22702049 — intervention group
Group type: COMPARATOR
Intervention: Direct anti-taken skin graft (control)
Number of subjects: 60
Study 19656277 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep curtailment (4 hours of sleep)
Number of subjects: 22
Study 19656277 — intervention group
Group type: COMPARATOR
Intervention: Control condition (9 hours of sleep)
Number of subjects: 22
Study 18353666 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg i.v.
Number of subjects: 83
Study 18353666 — intervention group
Group type: EXPERIMENTAL
Intervention: DHB 1.25 mg i.v.
Number of subjects: 83
Study 18353666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 83
Study 15809387 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified consent form alone (standard form modified to meet federal guidelines for readability and processability)
Number of subjects: 305
Study 15809387 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified consent form with verbal disclosure
Number of subjects: 305
Study 15809387 — intervention group
Group type: COMPARATOR
Intervention: Standard consent form alone
Number of subjects: 305
Study 15809387 — intervention group
Group type: COMPARATOR
Intervention: Standard consent form with verbal disclosure
Number of subjects: 305
Study 15809387 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified consent form
Number of subjects: 305
Study 12095953 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet intervention (n=58); weekly cooking course for 1 year, trained by professional chefs in the use of natural ingredients.
Number of subjects: 115
Study 12095953 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=55); advised to increase consumption of fruits and vegetables as recommended by WHO.
Number of subjects: 115
Study 12095953 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and control).
Number of subjects: 115
Study 11106139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 2075
Study 11106139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2075
Study 8780999 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physician-based counseling (3 to 5 min)
Number of subjects: 255
Study 8780999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 255
Study 8780999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 255
Study 8780999 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor (subsample of intervention participants)
Number of subjects: 255
Study 1858989 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22
Study 1858989 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 22
Study 6657201 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival transplantation
Number of subjects: 0
Study 6657201 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 0
Study 6657201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbate or citrate (orthomolecular therapy)
Number of subjects: 0
Study 31648008 — intervention group
Group type: EXPERIMENTAL
Intervention: 1SET (one set of muscle power training)
Number of subjects: 26
Study 31648008 — intervention group
Group type: EXPERIMENTAL
Intervention: 3SET (three sets of muscle power training)
Number of subjects: 26
Study 29304757 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day modified dot probe task as ABM training
Number of subjects: 77
Study 29304757 — intervention group
Group type: COMPARATOR
Intervention: 5-day classic dot probe task as placebo
Number of subjects: 77
Study 29304757 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (no intervention)
Number of subjects: 77
Study 26751262 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salicylate diet
Number of subjects: 30
Study 24754529 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL-PDT
Number of subjects: 44
Study 24754529 — intervention group
Group type: COMPARATOR
Intervention: IMIQ 5%
Number of subjects: 44
Study 22624290 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive compensation strategies
Number of subjects: 0
Study 22624290 — intervention group
Group type: COMPARATOR
Intervention: Head movement frequency
Number of subjects: 0
Study 20974319 — intervention group
Group type: EXPERIMENTAL
Intervention: Esreboxetine
Number of subjects: 267
Study 20974319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 18412236 — intervention group
Group type: EXPERIMENTAL
Intervention: NexStent plus FilterWire EX/EZ Emboli Protection System
Number of subjects: 454
Study 16213057 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release tablets containing felodipine under fed conditions
Number of subjects: 6
Study 16213057 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release tablets containing felodipine under fasting conditions
Number of subjects: 6
Study 16213057 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release tablets containing felodipine
Number of subjects: 6
Study 11845940 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia health education intervention
Number of subjects: 1197
Study 11845940 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 1197
Study 9952138 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous ondansetron (prophylaxis)
Number of subjects: 575
Study 9952138 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment with 1 mg intravenous ondansetron (if necessary)
Number of subjects: 575
Study 9952138 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis in female patients with a history of motion sickness or PONV undergoing highly emetogenic procedures
Number of subjects: 575
Study 9952138 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 575
Study 7573905 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 0.40 mg/kg bw and midazolam 0.075 mg/kg bw i.v. (test group P/M)
Number of subjects: 140
Study 7573905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg bw and midazolam 0.075 mg/kg bw i.v. (test group K25/M)
Number of subjects: 140
Study 7573905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg bw and midazolam 0.075 mg/kg bw i.v. (test group K50/M)
Number of subjects: 140
Study 7573905 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia (LA), articaine 4% plus epinephrine 1:200,000 (control group)
Number of subjects: 140
Study 2248758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna bathing
Number of subjects: 50
Study 2248758 — intervention group
Group type: COMPARATOR
Intervention: Control (no sauna bathing)
Number of subjects: 50
Study 6961763 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (mean daily dose 636 mg)
Number of subjects: 11
Study 6961763 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (mean dose 276 mg)
Number of subjects: 11
Study 6961763 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 11
Study 6961763 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study 31512828 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA irrigation for different time lengths (1 min, 3 min)
Number of subjects: 60
Study 31512828 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 60
Study 27612922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (4 mg), PRN regimen
Number of subjects: 30
Study 27612922 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone intravitreal implant (Ozurdex), single injection
Number of subjects: 30
Study 24633245 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid fat graft myringoplasty (HAFGM)
Number of subjects: 24
Study 24633245 — intervention group
Group type: COMPARATOR
Intervention: Modified fat graft myringoplasty (M-FGM)
Number of subjects: 24
Study 23800946 — intervention group
Group type: EXPERIMENTAL
Intervention: l-menthol
Number of subjects: 83
Study 23800946 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 83
Study 23042771 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose thoracic computed tomography (performed in the first and sixth years)
Number of subjects: 17500
Study 23042771 — intervention group
Group type: COMPARATOR
Intervention: Chest roentgenography (performed in the first year)
Number of subjects: 17500
Study 19204856 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referring ads
Number of subjects: 0
Study 19204856 — intervention group
Group type: COMPARATOR
Intervention: Other-referring ads
Number of subjects: 0
Study 21693030 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg/day from cycle day 1 to 9
Number of subjects: 214
Study 21693030 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate 100 mg/day from cycle day 3 to 7
Number of subjects: 214
Study 16191116 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation, 4-mm tip, n = 15
Number of subjects: 30
Study 16191116 — intervention group
Group type: COMPARATOR
Intervention: Cryoablation (CryoCor, San Diego, CA, USA), n = 15
Number of subjects: 30
Study 16191116 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RF ablation and cryoablation
Number of subjects: 30
Study 12097808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute moderate alcohol consumption
Number of subjects: 48
Study 12097808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10416139 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion sonography (SIS)
Number of subjects: 275
Study 7478121 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 70
Study 7478121 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 7478121 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 70
Study 2105548 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/day)
Number of subjects: 11
Study 2105548 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 11
Study 6106740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh expressed breast-milk during the day and milk formula at night
Number of subjects: 70
Study 6106740 — intervention group
Group type: COMPARATOR
Intervention: Milk formula only
Number of subjects: 70
Study 28801033 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention targeting lower limb strength and balance, tailored and progressive with seven recommended contacts over six months.
Number of subjects: 0
Study 27755474 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 107
Study 24884651 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased therapy time (from 8.6 to at least 13 hours a week) with interventions focused on strength, mobility, and balance.
Number of subjects: 0
Study 24884651 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy according to the Dutch stroke Guideline.
Number of subjects: 0
Study 23311172 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound granule prescription of thunberg fritillary bulb
Number of subjects: 238
Study 23311172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 20946685 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV with flexed knees (FK)
Number of subjects: 19
Study 20946685 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV with locked knees (LK)
Number of subjects: 19
Study 20946685 — intervention group
Group type: COMPARATOR
Intervention: Sham WBV with flexed knees (CON)
Number of subjects: 19
Study 18674989 — intervention group
Group type: EXPERIMENTAL
Intervention: CLBP group lifting differently than controls (n=46)
Number of subjects: 81
Study 18674989 — intervention group
Group type: COMPARATOR
Intervention: CLBP group lifting similarly to controls (n=35)
Number of subjects: 81